Skip to content
ModernDoc
Get the app
Condition research / Explore another topicSaved preview · Not clinically reviewed
Myeloma.

The long view. The new questions.
A clearer understanding.

A deeper look at the research on multiple myeloma.
For you. For someone you love. For the questions that keep coming.

3 saved articles · AI-written
Not clinically reviewed

The cover story · 2026 Aug 25

Daratumumab combination produced more deep treatment responses

Patients with newly diagnosed multiple myeloma who were not having an initial transplant received a combination including daratumumab or the comparison combination without it. More patients receiving daratumumab reached complete response or better and tested negative for minimal residual disease. These responses were more often sustained, while progression-free survival among patients testing negative showed only a nonsignificant trend favoring daratumumab. The trial enrolled patients who were transplant-ineligible or deferred transplant as initial therapy, so it does not establish the same result for all newly diagnosed patients. Among patients who achieved minimal-residual-disease negativity, the progression-free-survival difference was not statistically significant, so an advantage in that subgroup remains uncertain. The median follow-up was 58.7 months, so outcomes beyond that period are not established.

Read the story ↗

Research readings

A closer reading.

Study readings

Daratumumab combination produced more deep treatment responses

Patients with newly diagnosed multiple myeloma who were not having an initial transplant received a combination including daratumumab or the comparison combination without it. More patients receiving daratumumab reached complete response or better and tested negative for minimal residual disease. These responses were more often sustained, while progression-free survival among patients testing negative showed only a nonsignificant trend favoring daratumumab. The trial enrolled patients who were transplant-ineligible or deferred transplant as initial therapy, so it does not establish the same result for all newly diagnosed patients. Among patients who achieved minimal-residual-disease negativity, the progression-free-survival difference was not statistically significant, so an advantage in that subgroup remains uncertain. The median follow-up was 58.7 months, so outcomes beyond that period are not established.

2 min read · 2026 Aug 25

Study readings

Continuing zoledronic acid reduced bone disease progression

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

2 min read · 2026 Sep

Study readings

Elotuzumab regimens showed mixed side-effect risks

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

2 min read · 2026 Dec

Follow your curiosity.

3 articles

Study readings

Daratumumab combination produced more deep treatment responses

Patients with newly diagnosed multiple myeloma who were not having an initial transplant received a combination including daratumumab or the comparison combination without it. More patients receiving daratumumab reached complete response or better and tested negative for minimal residual disease. These responses were more often sustained, while progression-free survival among patients testing negative showed only a nonsignificant trend favoring daratumumab. The trial enrolled patients who were transplant-ineligible or deferred transplant as initial therapy, so it does not establish the same result for all newly diagnosed patients. Among patients who achieved minimal-residual-disease negativity, the progression-free-survival difference was not statistically significant, so an advantage in that subgroup remains uncertain. The median follow-up was 58.7 months, so outcomes beyond that period are not established.

2 min read · 2026 Aug 25

Study readings

Continuing zoledronic acid reduced bone disease progression

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

2 min read · 2026 Sep

Study readings

Elotuzumab regimens showed mixed side-effect risks

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

2 min read · 2026 Dec

A publication for curiosity.

AI-written. Not clinically reviewed. Selected sources, not a complete review. No personal treatment matching.

Article revisions preserve earlier writing. Article dates and source-check dates describe different events. Email updates and automatic research refresh are unavailable during this pilot.